Adherence of patients with atrial fibrillation after acute coronary syndrome to antithrombotic therapy at stage III of cardiac rehabilitation: data from the local register of the Kirov region

Aim      To evaluate the quality of antithrombotic therapy (ATT) in patients with atrial fibrillation (AF) after acute coronary syndrome (ACS) at stage 3 of rehabilitation.

Material and methods  The registry included 163 patients with AF (mean age, 65.0 [59.0; 72.0] years; 55.8 % men) undergoing rehabilitation after ACS (ACS <1 month ago) in the hospital of the Kirov State Medical University.

Results Recommendations for 73.6 % of patients on ATT provided upon discharge from the hospital after stage 2 of rehabilitation were consistent with clinical guidelines (CG). During the entire stage 3, 25.8% of patients had acute cardiovascular complications (CVC) or urgent interventions (8.0% died). Furthermore, the ATT was actually consistent with CG only in 9.2 % of patients; in 21.5 %, errors in changing the ATT timing were detected; and in 84.1 %, various mistakes in the control of international normalized ratio were observed. On the whole, 3.6% of patients incorrectly adjusted their ATT independently, and for 15.3%, the attending physician made incorrect APT adjustments.

Conclusion      In AF patients after ACS who were undergoing stage 3 of rehabilitation, the quality of the ATT was low despite the recommendations at discharge from the hospital, which depended not only on the patient but also on the attending physician.

1. Authors/Task Force Members, Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. European Heart Journal. 2012;33(21):2719–47. DOI: 10.1093/eurheartj/ehs253

2. Sulimov V.A., Golitsin S.P., Panchenko E.P., Popov S.V., Revishvili A.Sh., Shubik Yu.V. et al. Diagnosis and treatment of atrial fibrillation. Recommendations of RSC, RSSA and ACVS. Russian Journal of Cardiology. 2013;18(4 S3):5–100.

3. Sycheva N.A., Koroleva L.Yu., Nosov V.P., Kovaleva G.V., Paikova N.N., Volkova A.T. et al. Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study. Kardiologiia. 2020;60(7):53–63. DOI: 10.18087/cardio.2020.7.n954

4. Tatarintseva Z.G., Kosmachyeva E.D., Porhanov V.A. Anticoagulant therapy in atrial fibrillation with acute coronary syndrome in real clinical practice according to the total register of acute coronary syndrome in the Krasnodar Territory. Kardiologiia. 2018;58(S7):55–64. DOI: 10.18087/cardio.2490

5. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal. 2018;39(19):1726–1735a. DOI: 10.1093/eurheartj/ehy162

6. Garganeeva A.A., Kuzheleva E.A., Tukish O.V. The role of treatment adherence after myocardial infarction (according to the acute myocardial infarction registry). Complex Issues of Cardiovascular Diseases. 2019;8(4):56–64. DOI: 10.17802/2306-1278-2019-8-4-56-64

7. Bubnova M.G., Aronov D.M. Cardiac rehabilitation: stages, principles and international classification of functioning (ICF). Preventive medicine. 2020;23(5):40–9. DOI: 10.17116/profmed20202305140

8. Tarlovskaya E.I., Dorofeeva Yu.A., Malchikova S.V. Retrospective analysis of the clinical status of patients with atrial fibrillation preceding acute coronary syndrome: local register data. Russian Heart Journal. 2017;16(4):235–45.

9. Dorofeeva Yu.A., Tarlovskaya E.I., Malcikova S.V. A retrospective assessment of polymorbidity in patients with atrial fibrillation before hospitalization for acute coronary syndrome. Cardiology in Belarus. 2017;9(3):450–3.

10. Tarlovskaya E.I., Dorofeeva Yu.A., Malcikova S.V. A retrospective analysis of the quality of treatment preceding acute coronary syndrome in real outpatient practice in patients with atrial fibrillation: local register data. Kardiologiia. 2018;17(S3):27–35. DOI: 10.18087/cardio.2432

11. Dorofeeva Yu.A., Tarlovskaya E.I. The quality of treatment of patients with atrial fibrillation, depending on the index of polymorbidity, preceded hospitalization for acute coronary syndrome. Kardiologiia. 2018;17(S5):54–9. DOI: 10.18087/cardio.2478

12. Zykov M.S., Grigorovich M.S., Fedorets V.N. Long-term consequences of an atypical myocardial infarction in a young patient. Vyatka Medical Bulletin. 2021;69(1):116–20. DOI: 10.24411/2220-7880-2021-10165

13. Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu. The problem of adherence in modern medicine: solution possibilities, influence on the effectiveness of therapy and the outcomes of the disease. Rational Pharmacotherapy in Cardiology. 2017;13(4):519–24. DOI: 10.20996/1819-6446-2017-13-4-519-524

14. Sedykh D.Yu., Petrov G.P., Kashtalap V.V. Differences in adherence behaviour patterns in patients with primary and recurrent myocardial infarction. Complex Issues of Cardiovascular Diseases. 2018;7(4):15–25. DOI: 10.17802/2306-1278-2018-7-4-15-25

15. Glantz SA. Primer of biostatistics. -M.: Praktika;1998. - 459 p. https://medstatistic.ru/articles/glantz.pdf. ISBN 5-89816-009-4

16. Federal State Statistics Service. Russia in numbers 2019. A brief statistical collection. -M.: Rosstat;2019. - 549 p. ISBN 978-5-89476-465-8

17. Boldueva S.A., Soloveva M.V., Oblavatcky D.V., Feoktistova V.S. Myocardial Infarction in the Group of Patients With Atrial Fibrillation. Kardiologiia. 2020;60(1):53–61. DOI: 10.18087/cardio.2020.1.n620

18. Kundu A. Recent Trends In Oral Anticoagulant Use And Post-Discharge Complications Among Atrial Fibrillation Patients With Acute Myocardial Infarction. Journal of Atrial Fibrillation. 2018;10(5):1749. DOI: 10.4022/jafib.1749

19. Zeymer U, Annemans L, Danchin N, Pocock S, Newsome S, Van de Werf F et al. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. European Heart Journal: Acute Cardiovascular Care. 2019;8(2):121–9. DOI: 10.1177/2048872618769057

20. Biasco L, Radovanovic D, Moccetti M, Rickli H, Roffi M, Eberli F et al. New-onset or Pre-existing Atrial Fibrillation in Acute Coronary Syndromes: Two Distinct Phenomena With a Similar Prognosis. Revista Española de Cardiología (English Edition). 2019;72(5):383–91. DOI: 10.1016/j.rec.2018.03.002

21. Stenestrand U. Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term Outcome: A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation. 2005;112(21):3225–31. DOI: 10.1161/CIRCULATIONAHA.105.552984

22. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet. 2013;381(9872):1107–15. DOI: 10.1016/S0140-6736(12)62177-1

23. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal. 2015;169(4):472-478.e5. DOI: 10.1016/j.ahj.2014.12.006

24. Pavlova T.V., Duplyakova P.D., Shkaeva O.V., Krivova S.P. Subanalysis of the AUGUSTUS trial. Russian Journal of Cardiology. 2020;25(S3):70–5. DOI: 10.15829/1560-4071-2020-4104